Azelis extends agreement further with Tagra Biotechnologies with an exclusive distribution agreement in France and Benelux

Azelis has been appointed as exclusive distributor by Tagra Biotechnologies to offer their range of Release on Demand™ (RND™) micro capsules in France and Benelux for all personal care applications. This new partnership builds on an existing partnership between the two companies in Canada, China, India, Australia, New Zealand and most of Europe.

Lito Ickowicz, Director Business Development, Tagra Biotechnologies states: “We are very happy with the extension. Azelis is a long-trusted partner of Tagra and we work well together, so the decision to further expand came only naturally to us. Together we aim to offer customers high quality technical service and innovative application insights.”

Tony Craske, Market Segment Director, Azelis EMEA adds: “We are delighted to expand our partnership with Tagra once again. Azelis is well placed to increase market penetration in France and Benelux, and Tagra’s patented technology for the encapsulation of actives, UV filters and pigments is a welcome addition to our portfolio to these markets. We both have a high focus on innovation and Tagra’s market-leading ingredients will help our customers improve overall product performance.”

Tagra Biotechnologies is the only company to patent the RND™ Microencapsulation Technology a method of providing stability, efficiency and controlled/immediate release for non-water soluble ingredients. Azelis’ success relies on both the business and technical excellence of its people and the high quality ingredients delivered by principals. Given the strong technically-driven sales model of the team Azelis has confidence to grow the business further together with Tagra in France.

This technology enables the production of encapsulated ingredients including actives, vitamins, essential oils, flavonoids, silicones, pigments and sunscreens, all conforming to worldwide cosmetic regulations and suitable for a wide range of formulations. The agreement is effective immediately.